Article Text

Download PDFPDF
B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response
  1. Kristine P Ng,
  2. Geraldine Cambridge,
  3. Maria J Leandro,
  4. Jonathan C W Edwards,
  5. Michael Ehrenstein,
  6. David A Isenberg
  1. Centre for Rheumatology, University College London, London, UK
  1. Correspondence to:
    Professor D A Isenberg
    Centre for Rheumatology, Room 331, 3rd floor, Windeyer Building, 46 Cleveland Street, London W1T 4JF, UK; D.Isenberg{at}


Objectives: To describe the long-term clinical outcome and safety profile of B cell depletion therapy (BCDT) in patients with systemic lupus erythematosus (SLE). It was also determined whether baseline parameters can predict the likelihood of disease flare.

Methods: 32 patients with refractory SLE were treated with BCDT using a combination protocol (rituximab and cyclo-phosphamide). Patients were assessed with the British Isles Lupus Assessment Group (BILAG) activity index, and baseline serology was measured. Flare was defined as a new BILAG ‘A’ or two new subsequent ‘B’s in any organ system.

Results: Of the 32 patients, 12 have remained well after one cycle of BCDT (median follow-up 39 months). BCDT was followed by a decrease of median global BILAG scores from 13 to 5 at 6 months (p = 0.006). Baseline anti-extractable nuclear antigen (ENA) was the only identified independent predictor of flare post-BCDT (p = 0.034, odds ratio = 8, 95% CI 1.2 to 55) from multivariable analysis. Patients with low baseline serum C3 had a shorter time to flare post-BCDT (p = 0.008). Four serious adverse events were observed.

Conclusion: Autoantibody profiling may help identify patients who will have a more sustained response. Although the long-term safety profile of BCDT is favourable, ongoing vigilance is recommended.

  • BCDT, B cell depletion therapy
  • BILAG, British Isles Lupus Assessment Group
  • CyC, cyclophosphamide
  • dsDNA, double-stranded DNA
  • ENA, extractable nuclear antigen
  • PCR, protein creatinine ratio
  • SLE, systemic lupus erythematosus

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Published Online First 5 April 2007

  • Competing interests: MJL has received funding from Roche Pharmaceuticals and GlaxoSmithKline Research and Development Ltd.